HEL24.3-OCT4-nEmGFP-A-G3, UHi001-B, HEL24.3-OCT4-nEmGFP
UHi006-A-2
General
Cell Line |
|
| hPSCreg name | UHi006-A-2 |
| Cite as: | UHi006-A-2 (RRID:CVCL_LJ88) |
| Alternative name(s) |
HEL24.3-OCT4-nEmGFP-A-G3, UHi001-B, HEL24.3-OCT4-nEmGFP
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UHi006-A (HEL24.3) UHi006-A-1 (UHi001-A, HEL24.3-SOX2-nTdT-C9-H5, HEL24.3-SOX2-nTdT) BIHi001-A (BCRT-3, BCRT#1) UOSi001-B (MIFF3, MIFF-3, ShiPS-MIFF3) UOSi001-A (MIFF1, ShiPS-MIFF1, MIFF-1) BIHi001-A-1 (iBCRT Cas9v1-3G-Kl.16) |
| Last update | 12th August 2020 |
| User feedback | |
Provider |
|
| Generator |
University of Helsinki (UH)
Contact:
University of Helsinki (UH) |
| Owner | University of Helsinki (UH) |
| Distributors | |
| Derivation country | Finland |
External Databases |
|
| BioSamples | SAMEA104277230 |
| Cellosaurus | CVCL_LJ88 |
| Wikidata | Q54990148 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Caucasian, White |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
SNP typing array
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA103885930 |
Ethics
Also have a look at the ethics information for the parental line
UHi006-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
UHi006-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-3 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
||||
| SOX2 |
Yes |
|
||||
| LIN28A |
Yes |
|
Differentiation Potency
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
In vivo teratoma
In vitro spontaneous differentiation
In vitro directed differentiation
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XY
Passage number: 36
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.